Sanofi SNY announced that the European Medicines Agency (EMA) has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, for treating IgG4-related disease (IgG4-RD). IgG4 ...

Paris: Sanofi has announced that the European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible ...

EMA grants orphan designation to Sanofi’s rilzabrutinib, a reversible covalent BTK inhibitor, for IgG4-related disease: Paris Saturday, August 16, 2025, 09:00 Hrs [IST] Sanofi a ...

In patients with IgG4-related disease, the serum IgG4 concentration is typically high and often very, very high. Example, elevated up to five or 10 times the upper limit of normal is not unusual ...

This landmark study provides the first population-based estimates of immunoglobulin G4-related disease (IgG4-RD) in the U.S., revealing a 2.5-fold higher mortality risk in IgG4-RD patients versus ...

The same is true for retroperitoneal fibrosis or Ormand's disease as it was termed when it was described in the 1940s. Retroperitoneal fibrosis is also part of IgG4-related disease.

Researchers conducted a retrospective study of 328 patients (69% men) diagnosed with IgG4-related disease at the Massachusetts General Hospital - Rheumatology Clinic, Boston, who met the American ...

--Amgen announced today that the U.S. Food and Drug Administration has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease. "The FDA approval ...

Compared with the placebo, inebilizumab reduced the risk for IgG4-RD flares by 87% during the 52-week trial period (hazard ratio, 0.13; P < .0001). All the secondary endpoints showed improvement ...

Silent Lungs, Hidden Clues: What Chest CTs Reveal About IgG4-Related Disease —Investigators in Argentina recently examined a small subset of patients with immunoglobulin G4-related disease (IgG4 ...

Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at ...

Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025Additional orphan designation underscores Sanofi commitment to advancing ...